Nouvelle déclaration d'incident
No de la demande: 2020-2312
Numéro de référence du titulaire d'homologation: 2020-CA-000043
Nom du titulaire (nom légal complet, aucune abbréviation): The Hartz Mountain Corporation
Adresse: 400 Plaza Drive
Ville: Secaucus
État: New Jersey
Pays: USA
Code postal /Zip: 07094-3688
Incident chez un animal domestique
Pays: CANADA
État: ONTARIO
ARLA No d'homologation 30731 ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: Hartz UltraGuard Pro Drops for Dogs Over 28 kg
Oui
Inconnu
Site: Animal / Usage sur un animal domestique
Propriétaire de l'animal
Dog / Chien
Rottweiler
1
Femme
8
85
lbs
Cutanée
>1 mo <= 6 mos / > 1 mois < = 6 mois
>24 hrs <=3 days / >24 h <=3 jours
Système
>1 mo and <= 2mos / >1 mois et < = 2mois
Oui
Non
Fully Recovered / Complètement rétabli
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 13-Jan-2020, a 8 year old, 85 pound, neutered, female, Rottweiler dog, in unknown condition, with concomitant medical condition of pyometra, was administered 1 tube of Hartz UltraGuard Pro Drops for Dogs Over 28 kg (Phenothrin (Sumithrin) / S Methoprene) via the topical route by the animal owner. On approximately 15-Jan-2020, the dog developed generalized alopecia. On approximately 10-Feb-2020, the dog was administered 1 tube of Hartz UltraGuard Pro Drops for Dogs Over 28 kg (Phenothrin (Sumithrin) /S Methoprene) via the topical route by the animal owner. The liquid did not absorb post application, as the previous dose had. On approximately 17-Feb-2020, the dog¿¿¿¿¿¿s clinical sign of generalized alopecia worsened and the dog exhibited desquamation. The dog was evaluated by a veterinarian and a skin scraping was performed and there were no abnormalities detected. No additional treatments were provided. On approximately 10-Mar-2020, the clinical signs resolved and the dog recovered. Discontinuing use of product and further consultation with a veterinarian to rule out other possible etiologies was recommended. No further information was received in this case.
Mineure
The information contained in this report is based on self-reported statements provided to the registrant during telephone Interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and can not form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.